Clinical Trial Update: Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial of sotagliflozin in heart failure with preserved ejection fraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Sotagliflozin (sotagliflozin)

Snippet

Sponsor: Juan Badimon | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 4 | Status: COMPLETED